Completed NCT02422186
This study is completed in the United States, in France, in the United Kingdom, .... It is testing efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression.
In United Kingdom Depression Drug i A study involving a medication or substance. Over 65 Years
Countries United States, France, United Kingdom, ...
Sponsor Janssen Research & Development, LLC
Condition Depression Completed NCT03745820
This study is completed in the United States, in the United Kingdom, in Germany, .... It is testing Safety and Efficacy of BIIB104 for schizophrenia.
In United Kingdom Schizophrenia Drug From 18 Years to 55 Years
Countries United States, United Kingdom, Germany, ...
Sponsor Biogen
Condition Schizophrenia Completed NCT01371799
This study is completed in the United Kingdom. It focuses on Schizophrenia.
In United Kingdom Schizophrenia Drug From 18 Years to 55 Years
Countries United Kingdom
Sponsor GlaxoSmithKline
Condition Schizophrenia Completed NCT03559192
This summary needs review. Please check the official study record and contact the research team for details.
In United Kingdom Depression Drug From 18 Years to 64 Years
Countries United States, United Kingdom, Germany, ...
Sponsor Janssen Research & Development, LLC
Condition Depression Completed NCT03374475
This study is completed in the United States, in the United Kingdom, in Belgium, .... It focuses on depression.
In United Kingdom Depression Drug From 18 Years to 55 Years
Countries United States, United Kingdom, Belgium, ...
Sponsor Janssen Research & Development, LLC
Condition Depression Completed NCT04943796
This study is completed in Canada, in the United Kingdom, in Switzerland, .... It focuses on ADHD.
In United Kingdom ADHD Other Over 18 Years
Countries Canada, United Kingdom, Switzerland, ...
Sponsor Takeda
Condition ADHD Terminated NCT05211947
This study was terminated in the United States, in Australia, in France, .... It focuses on schizophrenia.
In United Kingdom Schizophrenia Drug From 18 Years to 51 Years
Countries United States, Australia, France, ...
Sponsor Boehringer Ingelheim
Condition Schizophrenia Completed NCT03809325
This study is completed in France, in the United Kingdom, in Belgium, .... It focuses on Schizophrenia.
In United Kingdom Schizophrenia Drug Over 18 Years
Countries France, United Kingdom, Belgium, ...
Sponsor Janssen-Cilag International NV
Condition Schizophrenia Completed NCT00232687
This summary needs review. Please check the official study record and contact the research team for details.
In United Kingdom Schizophrenia Drug From 18 Years to 65 Years
Countries France, United Kingdom, Belgium, ...
Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition Schizophrenia Terminated NCT02566759
This summary needs review. Please check the official study record and contact the research team for details.
In United Kingdom Schizophrenia Drug From 18 Years to 55 Years
Countries United Kingdom
Sponsor Neurocrine Biosciences
Condition Schizophrenia Ongoing EUCTR 2004-000502-40
This study is ongoing in the United Kingdom. It focuses on Depression.
In United Kingdom Depression Other
Countries United Kingdom
Sponsor Southampton University Hospitals Trust
Condition Depression Completed NCT03568500
This study is completed in the United Kingdom. It focuses on schizophrenia.
In United Kingdom Schizophrenia Drug From 18 Years to 65 Years
Countries United Kingdom
Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition Schizophrenia